Mark Sabag - 12 Nov 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Reporting relationship: Executive Vice President, International Markets Commercial
Issuer ticker: TEVA
Reported as of: 12 Nov 2026
Net transaction value: -$1,973,544
SEC form: 4
Accepted by SEC: 12 Nov 2026, 16:12:16 UTC
Prior SEC filing: 06 Nov 2026
Source filing: View source filing
Reporting owner signature: /s/ Dov Bergwerk as attorney-in-fact for Mark Sabag

Filing notes and source

Key filing fact

Mark Sabag filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 12 Nov 2026.

Key facts

This page summarizes Mark Sabag's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Nov 2026, 16:12.

Change

Previous filing in this sequence was filed on 06 Nov 2026.
Current net transaction value: -$1,973,544.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001721442 Primary reporting owner

Sabag Mark

Relationship: Executive Vice President, International Markets Commercial
Address: C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL
Signature: /s/ Dov Bergwerk as attorney-in-fact for Mark Sabag
Signature date: 12 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TEVA transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +44,710
Change %: +55%
Price: $34.90^*
Shares after: 125,470
Date: 12 Nov 2026
Ownership: Direct

TEVA transaction

Ordinary Shares

Sale

Transaction value: -$1,973,544
Shares: -44,710
Change %: -36%
Price: $44.14
Shares after: 80,760
Date: 12 Nov 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TEVA transaction Derivative

Stock Options (right to buy)

Options Exercise

Transaction value
Shares: -44,710
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 12 Nov 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 44,710
Exercise price: $34.90
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.10 to $44.29, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F2

Stock options were granted on February 14, 2017, with 30,236 vested on each of February 14, 2018, February 14, 2019 and February 14, 2020, and 30,238 vested on February 14, 2021.

SEC remarks

Executive Vice President, International Markets Commercial